ReviewCellular oncology (Dordrecht, Netherlands)2026
Liquid biopsy in the clinical management of tumor of urinary system: current status and future developments.
Review in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Urinary system tumors are a major threat to human health. However, there is a lack of reliable non-invasive examinations for urinary system tumors. Liquid biopsy is an emerging method for detecting biomarkers in patients in recent years. Its components mainly include circulating tumor cells, circulating tumor DNAs, circulating-free DNAs, circulating-free RNAs, exosomes and tumor educated platelets. Liquid biopsy is considered to be of great significance for the diagnosis, prognosis, treatment monitoring and medication guidance of cancers. The non-invasive characteristics of liquid biopsy significantly improve patients’ compliance and make it possible to collect patient information in real time and continuously. In this review, we selected urinary system tumors as the clinical application subjects of liquid biopsy. We believe that liquid biopsy has great potential value and application prospects in the clinical treatment of urinary system tumors.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.